European Research Council project HYPER-INSIGHT
"Hypermutated tumors: insight into genome maintenance and cancer vulnerabilities provided by an extreme burden of somatic mutations" (ERC Starting Grant # 757700, to Fran Supek)
Summary of the HYPER-INSIGHT project:
DNA is the molecule of heredity: it encodes all the genetic information that is necessary for cells to survive, grow, divide and differentiate into tissues that make up organisms. When this information stored in DNA is changed, this is referred to as mutation. In humans and in animals more generally, mutations that happen in germline cells can lead to disease phenotypes in the offspring, while mutations in somatic cells can cause tumors (or, they may potentially contribute to aging of tissues). In many cancers, and potentially in some healthy cells, a large number of mutations can accumulate; this may happen, for instance, because a DNA repair system has failed, which is a common risk factor for cancer.
The HYPER-INSIGHT project is interested in what happens to cells after they accumulate a very large number of mutations -- a phenomenon called hypermutation. This can help us learn how the human cells copy and repair DNA, which may have important implications for cancer research and for evolutionary biology research. Additionally, cancer cells undergoing hypermutation might have a particularly strong dependency on certain genes on which normal cells do not depend on so strongly. We will also search for such genes, which represent vulnerabilities of cancer cells and might be potentially used therapeutically, to selectively target cancer cells while sparing healthy tissues. Because cancer is an increasingly heavy burden on aging societies of the developed world, we anticipate that our project and related projects that look for novel avenues for tumor therapy will in the long run bring societal benefit. Additionally, understanding the biological mechanisms of mutagenesis may further help with prevention of cancer and with gaining better insight into the mechanisms underlying genetic diseases.
Some of our recent research related with the HYPER-INSIGHT project:
We have examined genome sequences of thousands of tumors (of various cancer types) to search for unusual patterns in how mutations are distributed in the genome. This has led to a finding of the so-called ‘mutation fog’: a clustering pattern that reflects how sometimes the cellular DNA repair systems can, erroneously, start introducing mutations instead of correcting them (published as Mas-Ponte & Supek, Nature Genetics, 2020). This may help explain the differences in cancer propensity across individuals and across human tissues.
Next, we have examined a different kind of pattern: the density of mutations distributed across large swaths (a million nucleotides) of the human chromosomes. Remarkably this pattern allows a very accurate classification of tumors into tissues and subtypes, starting only from the mutational pattern (published as Salvadores, Mas-Ponte and Supek, PLOS Computational BIology, 2019), without necessity to consult e.g. gene expression data -- a standard tool for cancer typing. This opens new avenues for diagnosing cancer type by DNA sequencing from ‘liquid biopsies’ (cancer cells or cancer DNA in blood plasma), and for classifying the metastatic ‘cancers of unknown origin’.
Furthermore, we have examined how increased mutation burden of so-called ‘nonsense’ mutations affects human cells including tumors, which have a special mechanism -- so-called NMD -- that degrades genetic messages containing nonsense mutations. We found that this NMD mechanism dampens the results of cancer immunotherapy in many cancer patients, and that it can be predicted from the genome sequence of tumors which patients those are (Lindeboom, Vermeulen, Lehner & Supek, 2019, Nature Genetics). Our data strongly suggest pharmacological NMD inhibition could be used to potentiate tumor immunotherapy, guided by genomic markers.
Finally, we have analysed diverse mutation patterns (together with gene expression patterns and epigenomic patterns) occurring in tumor cell lines -- an experimental model of tumor biology, which is used by many labs around the world to test new cancer therapies. We found, suprisingly, that approximately 6% of all cancer cell lines may originate from a different tissue than originally thought, as classified by the mutational and gene regulation patterns, using a machine learning method (Salvadores, Fuster and Supek, 2020, Science Advances). This has important implications for experimentally testing new cancer therapies in cancer cell lines, because the tissue-of-origin has a strong effect on how the cancer cell lines respond to drugs.
Overall, our work on the HYPER-INSIGHT project highlights how examining mutational patterns in human cancer cells can provide new insight into carcinogenesis and also new avenues for treating cancer. We described the state-of-the-art on these topics in a review article in Supek & Lehner (2018) DNA Repair (special issue: "Cutting-edge Perspectives in Genomic Maintenance VI").
"Everything is theoretically impossible, until it is done." -- Robert A. Heinlein